Literature DB >> 25370901

Acute and fatal thrombocytopenic thrombotic purpura after a single dose of pemetrexed.

Irene Alabiso1, Chiara Baratelli, Maria Pia Brizzi, Raffaella Bitossi, Azzurra Ottone, Marco Tampellini.   

Abstract

CASE: Thrombocytopenic thrombotic purpura (TTP), a life-threatening event consisting of disseminated vascular thrombosis, has never been described before as a possible side effect of the anticancer drug pemetrexed. A 70 years old patient affected by a poorly differentiated non small cell lung cancer, subjected to his first pemetrexed administration, developed an acute thrombocytopenic thrombotic purpura, fatal in a few hours.
CONCLUSIONS: Pemetrexed can cause TTP. Clinicians have to be alert for the rapid onset and aggressiveness of this possible side effect. It is difficult to recognise the first signs and symptoms.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25370901     DOI: 10.1007/s11096-014-0032-9

Source DB:  PubMed          Journal:  Int J Clin Pharm


  10 in total

1.  [A case of rheumatoid arthritis associated with autoimmune hemolytic anemia due to weekly low-dose methotrexate therapy].

Authors:  K Yoshida; D Kurosaka; Y Ozawa; T Yokoyama; N Tajima
Journal:  Ryumachi       Date:  2000-08

2.  Immune hemolytic anemia after treatment with pemetrexed for lung cancer.

Authors:  Gun Min Park; Kyou Sup Han; Yoon Hwan Chang; Cheol Hyeon Kim; Jae Cheol Lee
Journal:  J Thorac Oncol       Date:  2008-02       Impact factor: 15.609

3.  Severe immune hemolytic anemia due to pemetrexed in a patient with non-small cell lung cancer.

Authors:  Xiaojiang Sun; Liming Sheng; Qinghua Deng; Peng Liu; Ke Lu
Journal:  Pharmacology       Date:  2011-10-12       Impact factor: 2.547

4.  Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.

Authors:  Nicholas J Vogelzang; James J Rusthoven; James Symanowski; Claude Denham; E Kaukel; Pierre Ruffie; Ulrich Gatzemeier; Michael Boyer; Salih Emri; Christian Manegold; Clet Niyikiza; Paolo Paoletti
Journal:  J Clin Oncol       Date:  2003-07-15       Impact factor: 44.544

Review 5.  Pharmacology and mechanism of action of pemetrexed.

Authors:  Alex A Adjei
Journal:  Clin Lung Cancer       Date:  2004-04       Impact factor: 4.785

6.  Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.

Authors:  Nasser Hanna; Frances A Shepherd; Frank V Fossella; Jose R Pereira; Filippo De Marinis; Joachim von Pawel; Ulrich Gatzemeier; Thomas Chang Yao Tsao; Miklos Pless; Thomas Muller; Hong-Liang Lim; Christopher Desch; Klara Szondy; Radj Gervais; Christian Manegold; Sofia Paul; Paolo Paoletti; Lawrence Einhorn; Paul A Bunn
Journal:  J Clin Oncol       Date:  2004-05-01       Impact factor: 44.544

7.  Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura.

Authors:  Valentina Bianchi; Rodolfo Robles; Lorenzo Alberio; Miha Furlan; Bernhard Lämmle
Journal:  Blood       Date:  2002-07-15       Impact factor: 22.113

8.  Newly diagnosed versus relapsed idiopathic thrombotic thrombocytopenic purpura: a comparison of presenting clinical characteristics and response to treatment.

Authors:  Alberto Alvarez-Larrán; Julio del Río-Garma; Misericòrdia Pujol; Javier de la Rubia; Manuel Hernández-Jodra; Montserrat Borrell; José R González-Porras; José M García-Gala; Aurora Viejo; Lourdes Enríquez; Cristina Arbona; José A García-Erce; Ana G Noblejas; Arturo Pereira
Journal:  Ann Hematol       Date:  2009-02-11       Impact factor: 3.673

9.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.

Authors:  Giorgio Vittorio Scagliotti; Purvish Parikh; Joachim von Pawel; Bonne Biesma; Johan Vansteenkiste; Christian Manegold; Piotr Serwatowski; Ulrich Gatzemeier; Raghunadharao Digumarti; Mauro Zukin; Jin S Lee; Anders Mellemgaard; Keunchil Park; Shehkar Patil; Janusz Rolski; Tuncay Goksel; Filippo de Marinis; Lorinda Simms; Katherine P Sugarman; David Gandara
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544

10.  Thrombotic thrombocytopenic purpura and gemcitabine.

Authors:  Pashtoon Murtaza Kasi
Journal:  Case Rep Oncol       Date:  2011-03-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.